GeneDx Holdings (WGS) Preferred Stock Liabilities (2020 - 2021)
GeneDx Holdings' (WGS) quarterly Preferred Stock Liabilities came in at $334.4 million in Q2 2021, up 54.04% year-over-year from $217.1 million in Q2 2020, and little changed quarter-over-quarter from $334.4 million in Q1 2021.
Powered by 
Analysis
GeneDx Holdings (WGS) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
GeneDx Holdings (WGS) has reported Preferred Stock Liabilities for 2 consecutive years, with $334.4 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Preferred Stock Liabilities rose 54.04% year-over-year to $334.4 million in Q2 2021; TTM through Jun 2021 was $334.4 million, a 54.04% increase from a year earlier, with the FY2020 full-year figure at $334.4 million, up 54.04% from the prior year.
- Preferred Stock Liabilities was $334.4 million for Q2 2021 at GeneDx Holdings, roughly flat from $334.4 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $334.4 million in Q3 2020 and troughed at $217.1 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Natera | 53.05 Bn | 51.95 Bn | 486.15 Mn | - |
| 2 | Quest Diagnostics | 27.19 Bn | 26.87 Bn | 1.03 Bn | - |
| 3 | Labcorp Holdings | 25.93 Bn | 25.81 Bn | 1.11 Bn | - |
| 4 | Guardant Health | 23.97 Bn | 22.91 Bn | 219.03 Mn | - |
| 5 | Tempus AI | 13.64 Bn | 12.82 Bn | 274.25 Mn | - |
| 6 | Caris Life Sciences | 8.47 Bn | 7.68 Bn | 182.38 Mn | - |
| 7 | Sotera Health | 5.35 Bn | 4.99 Bn | 177.96 Mn | - |
| 8 | BillionToOne | 4.96 Bn | 4.41 Bn | 77.11 Mn | - |
| 9 | Adaptive Biotechnologies | 4.55 Bn | 4.21 Bn | 51.39 Mn | - |
| 10 | GeneDx Holdings | 3.01 Bn | 2.88 Bn | 78.24 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 334.44 Mn |
| Mar 31, 2021 | 334.44 Mn |
| Dec 31, 2020 | 334.44 Mn |
| Sep 30, 2020 | 334.44 Mn |
| Jun 30, 2020 | 217.12 Mn |